You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
福安藥業(300194.SZ):子公司奧硝唑原料藥通過CDE審批
格隆匯 08-09 16:56

格隆匯8月9日丨福安藥業(300194.SZ)公佈,公司全資子公司福安藥業集團重慶博聖製藥有限公司(簡稱“博聖製藥”)於近日在國家藥品監督管理局藥品審評中心(CDE)“原料藥、藥用輔料和藥包材登記信息公示”平台查詢獲悉,博聖製藥提交的“奧硝唑”原料藥註冊申請通過了CDE審批。

奧硝唑為抗感染類藥物,主要適用於治療由奧硝唑敏感的微生物引起的感染,如滴蟲病、阿米巴病、賈第蟲病、厭氧菌感染等。根據公示平台查詢顯示:奧硝唑原料藥目前除博聖製藥外,有6家企業原料藥通過審批,公司暫無法從公開渠道獲悉上述產品的市場銷售數據。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account